Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.95 EUR | -6.61% | +2.51% | +72.07% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.07% | 1.74B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.70% | 22.78B | |
-10.86% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk